Innate Pharma (IPHYF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2022 | 12-2021 | 06-2021 | 12-2020 | 06-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 6,708 | -62,478 | -28,579 | -73,089 | -11,379 |
| Depreciation Amortization | 2,160 | 5,438 | 2,612 | 64,879 | 7,398 |
| Other Working Capital | -11,681 | -11,694 | -15,228 | -56,208 | -63,418 |
| Other Operating Activity | 4,109 | -426 | 3,648 | 5,285 | 3,508 |
| Operating Cash Flow | $1,296 | $-69,160 | $-37,547 | $-59,133 | $-63,891 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -447 | -1,091 | -287 | -1,026 | -559 |
| Other Investing Activity | 27 | 6 | -11 | -14,247 | -12,773 |
| Investing Cash Flow | $-420 | $-1,085 | $-298 | $-15,273 | $-13,332 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | -1,022 | 31,728 | -1,477 | -1,344 | -1,320 |
| Financing Cash Flow | $-1,022 | $31,728 | $-1,477 | $-1,344 | $-1,320 |
| Exchange Rate Effect | -713 | -571 | -214 | 250 | -14 |
| Beginning Cash Position | 110,417 | 161,839 | 164,821 | 231,758 | 223,399 |
| End Cash Position | 109,558 | 122,754 | 125,286 | 156,258 | 144,841 |
| Net Cash Flow | $-859 | $-39,086 | $-39,536 | $-75,501 | $-78,558 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,296 | -69,160 | -37,547 | -59,133 | -63,891 |
| Free Cash Flow | 1,296 | -69,160 | -37,547 | -59,133 | -63,891 |